MXPA04000775A - Uso novedoso del 2 -[5-(4-fluorofenil) -3-piridilmetilamino-metil] -cromano y sus sales fisiologicamente aceptables. - Google Patents

Uso novedoso del 2 -[5-(4-fluorofenil) -3-piridilmetilamino-metil] -cromano y sus sales fisiologicamente aceptables.

Info

Publication number
MXPA04000775A
MXPA04000775A MXPA04000775A MXPA04000775A MXPA04000775A MX PA04000775 A MXPA04000775 A MX PA04000775A MX PA04000775 A MXPA04000775 A MX PA04000775A MX PA04000775 A MXPA04000775 A MX PA04000775A MX PA04000775 A MXPA04000775 A MX PA04000775A
Authority
MX
Mexico
Prior art keywords
pyridylmethylaminomethyl
chromane
fluorophenyl
physiologically acceptable
acceptable salts
Prior art date
Application number
MXPA04000775A
Other languages
English (en)
Inventor
Seyfried Christoph
Original Assignee
Merck Patent Ges Mit Baschrank
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Ges Mit Baschrank filed Critical Merck Patent Ges Mit Baschrank
Publication of MXPA04000775A publication Critical patent/MXPA04000775A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El (R/S) -(-/+)-2-[5-(4-fluorofenil)-3-piridilmetil-aminometill-cromano o una sal fisiologicamente aceptable del mismo y/o el (S)-(+)-2-[5-(4-fluorofenil)-3-piridilmetil-aminometil]-cromano o una sal fisiologicamente aceptable del mismo se utilizan para la fabricacion de un medicamento para el tratamiento de los trastornos del movimiento extrapiramidales y/o los efectos adversos en trastornos del movimiento extrapiramidales.
MXPA04000775A 2001-07-26 2002-07-10 Uso novedoso del 2 -[5-(4-fluorofenil) -3-piridilmetilamino-metil] -cromano y sus sales fisiologicamente aceptables. MXPA04000775A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01118097 2001-07-26
PCT/EP2002/007660 WO2003009835A2 (en) 2001-07-26 2002-07-10 Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts

Publications (1)

Publication Number Publication Date
MXPA04000775A true MXPA04000775A (es) 2004-04-20

Family

ID=8178137

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04000775A MXPA04000775A (es) 2001-07-26 2002-07-10 Uso novedoso del 2 -[5-(4-fluorofenil) -3-piridilmetilamino-metil] -cromano y sus sales fisiologicamente aceptables.

Country Status (24)

Country Link
US (1) US7872030B2 (es)
EP (1) EP1408964B1 (es)
JP (1) JP2004538289A (es)
KR (1) KR20040029325A (es)
CN (1) CN1292749C (es)
AR (1) AR037496A1 (es)
AT (1) ATE352302T1 (es)
AU (1) AU2002355170B2 (es)
BR (1) BR0211358A (es)
CA (1) CA2455621C (es)
CY (1) CY1107616T1 (es)
DE (1) DE60217870T2 (es)
DK (1) DK1408964T3 (es)
ES (1) ES2280602T3 (es)
HK (1) HK1068793A1 (es)
HU (1) HUP0402092A3 (es)
MX (1) MXPA04000775A (es)
MY (1) MY134059A (es)
PE (1) PE20030277A1 (es)
PL (1) PL208258B1 (es)
PT (1) PT1408964E (es)
RU (1) RU2297833C2 (es)
SI (1) SI1408964T1 (es)
WO (1) WO2003009835A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0613859B8 (pt) 2005-07-26 2021-05-25 Bial Portela & Ca Sa inibidores da comt, seus usos, e composição farmacêutica
EP1845097A1 (en) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
EP2124947B1 (en) 2007-01-31 2017-07-19 BIAL - Portela & Ca., S.A. Dosage regimen for comt inhibitors
CA2718772C (en) 2008-03-17 2017-05-02 David Alexander Learmonth Crystal forms of 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxy-pyridine-3-yl)[1,2,4]oxadiazol-5-yl]-3-nit robenzene-1,2-diol
CN105878242A (zh) 2009-04-01 2016-08-24 巴尔-波特拉及康邦亚股份有限公司 包括硝基儿茶酚衍生物的药物制剂及其制备方法
NZ714887A (en) * 2009-09-11 2019-07-26 Ionis Pharmaceuticals Inc Modulation of huntingtin expression
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
PT3604299T (pt) 2011-12-13 2023-10-31 Bial Portela & Ca Sa Composto químico útil como intermediário para a preparação de um inibidor de catecol-o-metiltransferase
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US576132A (en) * 1897-02-02 Current water-wheel
DE2364685C3 (de) 1973-12-27 1978-06-15 Beiersdorf Ag, 2000 Hamburg Phenoxyäthylamine
US4438119A (en) * 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
CA1337429C (en) 1983-12-05 1995-10-24 Guy Rosalia Eugene Van Lommen Derivatives of 2,2'-iminobisethanol
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
DE69123090D1 (de) * 1990-07-06 1996-12-19 Yoshitomi Pharmaceutical Kondensierte Thiophenverbindungen und deren Verwendung
DE4135474A1 (de) * 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
US5314888A (en) * 1992-02-21 1994-05-24 Trustees Of Tufts College Veterinary method for treating inappropriate elimination of urine in household pets
SI9300097B (en) 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
WO1993017670A1 (en) 1992-03-11 1993-09-16 Interneuron Pharmaceuticals, Inc. Reducing post-prandial fluctuations in plasma concentrations of large neutral amino acids (lnaa)
DE4226527A1 (de) 1992-08-11 1994-02-17 Merck Patent Gmbh 1,4-Benzodioxanderivate
GB9302622D0 (en) 1993-02-10 1993-03-24 Wellcome Found Heteroaromatic compounds
ZA954688B (en) 1994-06-08 1996-01-29 Lundbeck & Co As H Serotonin 5-HT1A and dopamin D2 receptor ligands
SI0707007T1 (en) * 1994-10-14 2002-04-30 Merck Patent Gmbh (R)-(-)-2-(5-(4-fluorophenyl)-3-pyridylmethylaminomethyl)chromane as CNS active agent
US5502080A (en) * 1994-11-01 1996-03-26 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of allergic disorders
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
US5541199A (en) * 1995-06-02 1996-07-30 American Home Products Corporation Chroman-2-ylmethylamino derivatives
US6114334A (en) * 1995-07-13 2000-09-05 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
GB9514380D0 (en) * 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
US5670667A (en) * 1995-07-25 1997-09-23 American Home Products Corporation Chroman-2-ylmethylamino derivatives
US5756521A (en) * 1996-04-03 1998-05-26 American Home Products Corporation Chroman-2-ylmethylamino derivatives
DE19648384A1 (de) 1996-11-22 1998-05-28 Merck Patent Gmbh Fluorene, Dibenzofurane und Dibenzothiophene
ATE253058T1 (de) * 1997-09-02 2003-11-15 Duphar Int Res Piperidin- und piperazin derivate als 5-ht1- rezeptor-agonisten
EP0900792B1 (en) 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
US6242456B1 (en) * 1998-03-09 2001-06-05 Trustees Of Tufts College Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
CN1155567C (zh) 1998-04-29 2004-06-30 惠氏公司 抑制精神的吲哚基衍生物
UA71590C2 (en) 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit

Also Published As

Publication number Publication date
ATE352302T1 (de) 2007-02-15
CN1535150A (zh) 2004-10-06
US7872030B2 (en) 2011-01-18
KR20040029325A (ko) 2004-04-06
HK1068793A1 (en) 2005-07-29
CA2455621A1 (en) 2003-02-06
AU2002355170B2 (en) 2007-06-07
DE60217870D1 (de) 2007-03-15
DK1408964T3 (da) 2007-05-21
MY134059A (en) 2007-11-30
US20040171645A1 (en) 2004-09-02
ES2280602T3 (es) 2007-09-16
RU2004105844A (ru) 2005-05-10
BR0211358A (pt) 2004-09-21
PL208258B1 (pl) 2011-04-29
DE60217870T2 (de) 2007-11-15
AR037496A1 (es) 2004-11-17
HUP0402092A3 (en) 2010-06-28
JP2004538289A (ja) 2004-12-24
HUP0402092A2 (hu) 2005-02-28
PT1408964E (pt) 2007-05-31
WO2003009835A2 (en) 2003-02-06
WO2003009835A3 (en) 2003-08-07
EP1408964A2 (en) 2004-04-21
RU2297833C2 (ru) 2007-04-27
SI1408964T1 (sl) 2007-06-30
CN1292749C (zh) 2007-01-03
EP1408964B1 (en) 2007-01-24
PE20030277A1 (es) 2003-03-25
PL367291A1 (en) 2005-02-21
CY1107616T1 (el) 2013-03-13
CA2455621C (en) 2010-11-16

Similar Documents

Publication Publication Date Title
GB0117645D0 (en) Therapeutic stratergies for prevention and treatment of alzheimers disease
GEP20074047B (en) Pramipexole once-daily dosage form
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
CO5271691A1 (es) Nuevos compuestos
CY1107616T1 (el) Καινοτομος χρηση της 2-[5-(4-φθοροφαινυλο)-3-πυριδυλομεθυλαμινομεθυλο]-χρωμανης και των φυσιολογικα αποδεκτων αλατων της
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
AP2004003124A0 (en) Thiazole and oxazole derivatives which modulate PPAR activity
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
MXPA03000439A (es) Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida.
MEP5608A (xx) Nova upotreba (r) – (-)-2-[5-(4-fluorofenil)-3-piridil- metilaminometil] - hromana i njegovih fiziološko prihvatljivi h soli
MY136449A (en) N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide for the treatment of cancer
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
MY128529A (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
HUP0402654A2 (hu) 2-[(2'-Halogén-3',5'-dialkoxi-fenil)-imino]-imidazolidin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
MY128882A (en) Novel use of substituted aminomethyl chromans
ATE392213T1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
NO20010984D0 (no) Anvendelse av R(+)-<alfa>-(2,3-dimetoksyfenyl)-1-[2-(4- fluorfenyl)etyl]-4-piperidinmetanol for behandling av søvnforstyrrelser
MXPA04001001A (es) PRAMIPEXOL PARA EL TRATAMIENTO DEL TRASTORNO DE HIPERACTIVIDAD Y DeFICIT DE LA ATENCION.
ITMI20011185A0 (it) Protesi per l'occlusione dell'auricola cardiaca sinistra con impiantotranscatetere
ITTO20010528A0 (it) Vite implantare per protesi dentaria.
AU2002229864A1 (en) Cysteine for oral administration for dry eye treatment
ITMI20022594A1 (it) Combinazione terapeutica per la cura dell'ipertensione.

Legal Events

Date Code Title Description
FG Grant or registration